Press Release (ePRNews.com) - TORONTO - Jun 28, 2018 - Join Andrew Roche, Ph.D., a senior member of ICON’s NASH team, on Tuesday, July 17, 2018, at 11a.m. EDT (4 p.m. BST/UK) as he speaks about overcoming the challenges and considerations associated with NASH clinical trials and examines potential strategies to address these challenges during trial design or study execution.
Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of clinical conditions which range from the relatively benign hepatic steatosis to the more serious non-alcoholic steatohepatitis (NASH) which puts subjects at significant risk of liver failure, cirrhosis and hepatocellular carcinoma.
Currently, there are no approved medicines to treat subjects with or at risk of developing NASH. However, a number of pioneering companies have taken up the challenge to address this unmet clinical need. One of the many challenges encountered during this process is the process of enrolling subjects into a clinical trial via utilization of centralized assessments of liver biopsy specimens. During the course of this discussion, ICON will share considerations that will aid cost-effective and timely enrollment of subjects.
Dr. Roche is Scientific Director of Global Validation and Scientific Affairs at ICON, a leader in clinical development for the biopharmaceutical industry.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
DISCLAIMER : If you have any concerns regarding this press release, please contact the Author / Media Contact / Business of this press release. ePRNews is not resposible for the accuracy of the news posted and do not endorse, support any product/services/business mentioned and hereby disclaims any content contained in this press release.